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Abstract: This study examined the differences in health spending within the World Health
Organization (WHO) Europe region by comparing the EU15, the EU post-2004, CIS, EU Candidate
and CARINFONET countries. The WHO European Region (53 countries) has been divided into the
following sub-groups: EU15, EU post-2004, CIS, EU Candidate countries and CARINFONET countries.
The study period, based on the availability of WHO Global Health expenditure data, was 1995 to 2014.
EU15 countries have exhibited the strongest growth in total health spending both in nominal and
purchasing power parity terms. The dynamics of CIS members’ private sector expenditure growth
as a percentage of GDP change has exceeded that of other groups. Private sector expenditure on
health as a percentage of total government expenditure, has steadily the highest percentage point
share among CARINFONET countries. Furthermore, private households’ out-of-pocket payments on
health as a percentage of total health expenditure, has been dominated by Central Asian republics for
most of the period, although, for the period 2010 to 2014, the latter have tended to converge with
those of CIS countries. Western EU15 nations have shown a serious growth of health expenditure far
exceeding their pace of real economic growth in the long run. There is concerning growth of private
health spending among the CIS and CARINFONET nations. It reflects growing citizen vulnerability
in terms of questionable affordability of healthcare. Health care investment capability has grown
most substantially in the Russian Federation, Turkey and Poland being the classical examples of
emerging markets.
Keywords: health economics; WHO; Europe; public health expenditure; private health expenditure
1. Introduction
Healthcare spending became a matter of academic attention in the early works of the American
economists Milton Friedman [1] and Selma Mushkin [2] ranging from the early 1920s until the
early 1950s. These publications are counted among the historical beginnings of the interdisciplinary
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knowledge, which became known as the science of health economics [3]. Why did it all begin in the U.S.,
given the fact that early institutionalized national health systems had roots in Europe from the XIX (19th)
century? In the U.S., since the 1840s up to the 1960s, according to available historical archives, there was
a steady and parallel growth of the average industry worker’s net salary and the price of an ordinary
physician examination [4]. After the 1950s, due to an array of socioeconomic changes and technology
driven causes, these two trends became divergent leading to obvious disparity [5]. European nations,
experiencing consecutive industrial revolutions were expanding their health care coverage within their
nations very gradually. During the early years of Bismarck’s leadership, healthcare was provided only
for industrial workers and their families from 1883 [6]. Beveridge evolved in the British mainland and
its overseas colonies with some distinctive advantages being introduced around 1911 [7,8]. Surprisingly,
the very first world’s healthcare system delivering universal health coverage for all its citizens including
the poorest ones, at the level of medical technology of its time, was Soviet Semashko back in the early
1930s [9,10].
Today in Europe, North America and many other industrialized contemporary societies of
Asia, real gross domestic product (GDP) growth is almost twice as slow as the long-term growth
of total health expenditure [5]. The most commonly cited causes for health expenditure growth are
advances in medical technology and pharmaceutical innovation [11], population aging [12], blossoming
of non-communicable “prosperity” diseases [13] and growing citizen expectations [14]. A deeper
understanding of long-term health expenditure patterns across geographies and jurisdictions might be
essential for shaping responses to this challenge in the future [15].
This study aimed to reveal and explain the causes of underlying differences in health spending
within the World Health Organization (WHO) Europe region by comparing the EU15, the EU
post-2004, Commonwealth of Independent States (CIS) [16], EU Candidate and Central Asian Republics
Information Network (CARINFONET) countries. This article contributes to the literature in several
ways. Firstly, the studies on comparative research of healthcare systems have been rather limited to
the Post-Soviet cultural space [15,17] outside the Russian language literature [18–20]. Secondly, it has
added to the research on institutional change, which has been ongoing within the WHO Europe region
since 1990 [21]. This concept of “transition” [22] from socialist centrally-planned economies, towards
market-driven capitalist societies took place after the end of the Cold War era throughout the 1990s [23]
and 2000s [24] alongside accelerated globalisation. This process had a profound impact on healthcare
establishments [25], which is further explored alongside several distinctive development pathways.
Apparently, 45 years of the Cold War era [26] and consecutive accelerated globalisation [27]
since 1991, has left a deep imprint on many spheres of life including healthcare systems [28]. Today,
the major transnational associations on the continent are the European Union and the Commonwealth of
Independent States as a legal successor authority of the Union of Soviet Socialist Republics (USSR) [29].
There are as well, other countries with various degrees of legislative proximity to one or another.
The free-market or centrally-planned economic system establishment [30], prior to 1989 has had a
profound impact on healthcare provision and financing patterns [25].
2. Materials and Methods
The geopolitical landscape within the WHO Europe Region comprising 53 countries and a total of
800+ million people was observed here by delineating specific groups of nations. Therefore, the WHO
European Region was split into a total of five groups of nations (Table 1): EU15 (members of the
European Union prior to 2004, having the established free-market economies since the Cold War era),
the EU post-2004 (mostly former socialist, centrally-planned economies with the exceptions of Malta
and Cyprus), the CIS (Commonwealth of Independent States with membership similar to 1991, due to
the fact that all these countries shared the same Semashko healthcare systems), EU Candidate countries
(consisting of former Yugoslavia republics/Western Balkans and Turkey) and CARINFONET countries
(Central Asian nations, most of them members of the CIS, but represented a distinct subgroup of
nations due to their shared socioeconomic characteristics.
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Table 1. List of country groups observed.
EU15 EU Post-2004 CIS * CARINFONET ** EU Candidate Countries
Austria AUT Bulgaria BGR Armenia ARM Kazakhstan KAZ Albania ALB
Belgium BEL Croatia HRV Azerbaijan AZE Kyrgyzstan KGZ Montenegro MNE
Denmark DNK Cyprus CYP Belarus BLR Tajikistan TJK Serbia SRB
Finland FIN Czech RepublicCZE Kazakhstan KAZ Turkmenistan TKM
The former Yugoslav Republic
of Macedonia MKD
France FRA Estonia EST Kyrgyzstan KGZ Uzbekistan UZB Turkey TUR
Germany DEU Hungary HUN Republic ofMoldova MDA Bosnia and Herzegovina BIH
Greece GRC Latvia LVA Russian FederationRUS
Ireland IRL Lithuania LTU Tajikistan TJK
Italy ITA Malta MLT Turkmenistan TKM
Luxembourg LUX Poland POL Ukraine UKR
Netherlands NLD Romania ROU Uzbekistan UZB
Portugal PRT Slovakia SVK
Spain ESP Slovenia SVN
Sweden SWE
United Kingdom
GBR
Note: * The Commonwealth of Independent States (CIS) formed when the former Soviet Union dissolved in 1991.
** CARINFONET (Central Asian Republics Information Network) Steering Group.
The selected indicators of health spending were: total health expenditure as a percentage
of Gross Domestic Product (GDP); public sector expenditure on health as a percentage of GDP;
private sector expenditure on health as a percentage of GDP; total health expenditure, purchasing power
parity, USD per capita; public expenditure on health, purchasing power parity, USD per capita;
public sector expenditure on health as a percentage of total government expenditure; private households’
out-of-pocket payments on health as a percentage of total health expenditure. While the WHO and
The Organisation for Economic Co-operation and Development (OECD) estimates were used for the
first indicator, the WHO estimates were only utilized for the others.
The data source selected, among OECD Health, EuroStat, World Bank Health Data and a few
other similar sources, was the WHO Global Health Expenditure Database due to its broadest possible
coverage of political entities and highly reliable methodology of data collection giving insight into
the exact fiscal flows within various national health systems [31]. The time horizon observed was
1995–2014 for most of the indicators, due to data gaps in chronology for the earlier years. For total
health expenditure, expressed as a percentage of GDP, and public health spending, the time horizon
was 1990–2014. Coverage of all observed nations, with these aggregate data, was complete and no
significant data gaps were present.
Whenever possible, the OECD definition of total health expenditure was applied in this study
(for details see [32], p. 89). It consisted of: household health expenses, including goods and
services purchased at the consumer’s own initiative and the cost sharing part of publicly financed or
supplied care; government-supplied health services, including those in schools, prisons and armed
forces and special public health programs such as vaccination; investment in clinics, laboratories,
etc.; administration costs; research and development, excluding outlays by pharmaceutical firms;
industrial medicine; outlays of voluntary and benevolent institutions. In the case of most central and
eastern European countries, the following had to be included: direct state budget allocated to the
health sector, state subsidies to the mandatory health insurance system; mandatory health insurance
contributions by employers and employees; direct health expenditure of employers for running
industrial medical facilities; direct health expenditures of ministries and governmental agencies;
charity health expenditures; foreign assistance; outstanding debt at the end of the year; private health
insurance and direct private health charges [33]. It is important to ensure that funding from the general
budget revenues and health insurance contributions do not overlap [34].
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3. Results
The first part of the analysis reported in this section was related to the GDP of the five groups of
nations. This data presented was estimated by the WHO.
Figures 1 and 2 present the total health expenditure as a percentage of GDP. Total health
expenditures are the sum of general government expenditure on health and private expenditure
on health.
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The data of Figure 2, for OECD member states, was taken from the OECD Health Database [35].
For non-OECD countries, the data was as reported by the country in the European Health for All
database (HFA-DB) [36] and may not have necessarily corresponded to the common WHO or OECD
definition [37].
Comparing the health expenditure as a percentage of GDP, presented in Figures 1 and 2, the data
of EU_Candidates differed significantly between both sources. There was a gap in the data as shown in
Figure 2 for the year 2011 and later for the EU_Before_May2004 group of nations. Nevertheless, both
estimates showed that health expenditure was a greater share of GDP for the EU_Before_May2004 group
of nations, and lower for the CARINFONET group. The EU_Before_May2004 group of nations had an
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increase in health expenditure as a percentage of GDP according to both data sources. Meanwhile,
the EU_After_May2004, CIS and EU_Candidates also showed an increase in health expenditure as a
proportion of GDP, but only in Figure 2, not confirmed by the WHO estimates (Figure 1).
Concerning the comparison between public- and private sector expenditure on health as a
percentage of GDP, Figures 3 and 4 present the WHO estimates.
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For the EU_Before_May2004 group of nations both public- and private sector expenditure on
health, as a percentage of GDP increased by two and 0.5 percentage points, respectively. This was in
accordance with the increase of the total health expenditure presented in Figures 1 and 2. This group
had the highest public sector expenditure and the second lowest private sector expenditure among
the five groups of nations. However, this group of nations had an increase in investment until 2009,
which stabilised after 2009.
The EU_After_May2004 group showed a similar tendency in public- and private sector expenditure
on health, as a percentage of GDP, as the other EU nations. Health expenditure, however, accounted for
a lower proportion of GDP for this group of countries.
These data show that the EU member nations—both those who were members before and after
May 2004—experienced increasing health expenditure GDP shares until 2009, but thereafter health
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expenditure accounted for a stable share of the economy. A comparison of Figures 1 and 2 shows that
the public sector health expenditure of each group was three to four times larger than the respective
private expenditure share.
Concerning the CIS and CARINFONET groups of nations, they presented a similar pattern in
the total health expenditure, as a percentage of GDP, both in public and private sectors. Nevertheless,
the CARINFONET had a generally lower investment in healthcare, and in public spending, of about
one point in percentage point share terms. Concerning the private investment, they presented a
similar level of investment (by the percentage of GDP). However, the CIS group significantly increased
their private investment in 1995–1998 and 2008–2009. The CIS group of nations (which included
the CARINFONET group) had a stabilised level of total investment (about 6% of GDP). The public
sector expenditure remained stabilised between 3% and 4% of GDP, meanwhile the private sector
expenditure increased from 2% to more than 3% of GDP. The public and private expenditure appeared
to be balanced under the CIS group of nations.
Concerning the EU_Candidate countries, the public sector expenditure on health remained stable,
but the private sector suffered a decrease of almost one percentage point from 3.2% to 2.5% of GDP.
This trend of lower expenditure in the private sector, among the EU Candidate economies, was opposite
as a tendency with regard to the other groups of nations. The EU_Candidates private expenditure
seemed to follow an approximation to the level of private expenditure of the EU nations.
The total health expenditure, purchasing power parity (PPP), in USD per capita, and the public
sector expenditure on health, purchasing power parity, in USD per capita, according to the WHO
estimates, is presented in Figures 5 and 6.
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Figures 7 and 8 present the public- and private sector expenditure on health, as a percentage of total
health expenditure, according to the WHO estimates. This information was in accordance with public
sector expenditure on health, as a percentage of GDP, presented in Figure 2, but showed the government
expenditure in public sector health. It can be seen that the EU_Before_May2004 group of nations had a
higher investment in health than the other groups. The EU_Before and After_May2004 had an increase
until 2009, but after that it remained stable until 2013, about 16% for EU_Before_May2004 and 12%
for EU_After_May2004. The EU_Candidates aligned the public sector expenditure on health with
EU_After_May2004 since 2008. The CIS group of nations had a stabilised effort on expenditure in the
public health sector of around 10% of total government expenditure. The CARINFONET group of
nations had several fluctuations of public sector expenditure between 1995 and 2013.
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i r 9 presents the private households’ out-of-pocket payments on health as a p rcentage
of total health expenditure for the fiv groups of nations. This feature dominated by the
Central Asian republics (CARINFONET) for most of the period, shared with CIS values in la ter
years. The EU_B fore_May2004 and EU After_May2004 pres ted a lower and stable level of private
househ lds’ out-of-pocket spending on health, which was around 15% and 23% of total he lth
expenditure, respectively. Th se results were in accordance w th previous analysis of Figures 4–6.
The EU_Candidates’ group of nations made an effort to r duce its expenditure in this category and
stabilised after 2003, to around 33% to 36% of total health expenditure.
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4. Study Limitations
One of the possible methodological weaknesses f this study is the fact that reported annual values
of health spending by the major multilateral agencies such as the World Bank (WB) and OECD Health
may differ to a minor extent (up to +/− few percentage point shares). Geoeconomic division of WHO
European region into the five observed regions might be questioned to some extent, alongside other
major division lines separating diverse health financing and provision traditions across Europe.
One such possible division that might be objected to as an alternative core criterion is the separation
of the European health systems to Bismarck, Beveridge and Semashko route models, following their
historical order of appearance. Estimates for total expenditure on health produced by the WHO were
reliable to the greatest extent possible, based on the National Health Accounts [39] classification [40].
The sources included both nationally reported data and estimates from international organisations
namely: WHO, the United Nations (UN), the International Monetary Fund (IMF), WB and OECD.
Therefore, they may differ somewhat from official national statistics reported by countries [41].
The WHO estimates for this indicator are generally more accurate [42]. Therefore, the authors worked
with the best publicly accessible data for international comparisons of inherently different economic
systems. However, the core findings of the study should not be questioned based on these minor
differences in accounting practices across jurisdictions.
5. Discussion
The historical legacy of the Cold War era and accelerated globalisation in the post-1989
period, has shaped economic systems throughout the European continent. During this process,
several distinctive geopolitical [43] and economic zones have emerged [44,45]. This research
has explored the best publicly accessible international data sources on the long-term evolution
of healthcare-related spending. Comparison of these five groups of nations, sharing significant internal
similarities, reveals surprising findings which so far, remain unpublished in literature [46].
Since a lengthy time period was explored, there were roughly two different stages of historical
evolution particularly prominent on the eastern side of the former Iron Curtain frontier. For most of the
1990s the entire Eastern Europe, being mutually interdependent with the former USSR, was dragged
into the new Russian recession, bottoming out in 1998. This heavily reflected on demographic trends
of the time, healthcare investment and its outcomes in most of the former socialist countries. This early
transitional period was marked with difficulties, even with quite successful health reforms, such as the
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Polish [47], Hungarian [48] or Czech ones [49]. In the civil wars of the former Yugoslavia, sanctions
and waves of refugee migration devastated economies and led to a decade-long delay in significant
health reforms and spending growth [50]. This was most prominent in the largest country of the
region, Serbia [51], acting as the historical core for Yugoslavia after World War I and World War II [12].
Turkey had a rather slower pace of essential health system progress back in the 1990s [52].
The second, far more prosperous period, roughly began in the early 2000s, for most of the Eastern
European [53,54] and Balkan nations [55]. Since the beginning of the XXI (19th) century, just like the
Russian Federation’s [9], Turkey’s overall development and ability to increase health expenditure was
growing much faster in comparison to the high-income OECD economies [56]. The contemporary
Turkish health system delivered surprisingly well-balanced, and, to a large degree, cost-effective
spending mechanisms, leading to limited inequalities and medical care affordability [57].
The high-income Western European EU15 nations had rather steady and satisfactory,
overall economic growth spanning from 1989 to 2007 [58]. However, between 1990 and 2014,
these rich countries exhibited an exceptionally alarming rate of health spending growth, even when
their real GDP growth was taken into account [59]. This means that public cost containment policies,
conducted over the past thirty years, have been largely ineffective in dealing with this challenge [60].
Accelerated and advanced stage population aging [61] remains particularly prominent in Western,
Northern and Central Europe [62]. One should emphasize here that this core driver of health-spending
remains slightly less influential in Eastern European societies compared to EU15. This is due to
the fact that population-aging evolution, in Eastern Europe, is at an earlier stage, as was recently
documented in UN datasets, comprising data from the previous century [63]. Furthermore, the
Russian Federation’s early 2000s fertility-supportive policies gained momentum with a recent RANEPA
report [64] claiming total fertility growth rate [65], on average, from 1.3 to 1.7 children per woman,
over a decade long perspective [64]. Another fact is that life expectancies remain significantly lower
across the CIS nations [66] with men living shorter lives than women [67]. However, exploring the
core investment–output ration between health spending and longevity, throughout the vast Eastern
EU-post-2004, the Balkans and CIS region provide another surprising perspective. Life expectancy
gains in South-East Europe [68] were quite similar to EU-post-2004 members at a far lower healthcare
investment increase [69]. Furthermore, the CIS relationship curve, between current total health
expenditure and longevity growth margin, although positioned in the lower quadrant, in comparison
to the other two regions, has the steepest upward pathway, promising improvement in the future [70].
Therefore, it seems that the EU nations (before and after May 2004), had an increase of expenditures
as a percentage of GDP until 2009, but stopped the further growth after this year [71]. This is clearly
attributable to the fiscal austerity policies triggered by the Global Recession, following the bankruptcy
of the Lehman Brothers in 2007 [72]. Such strategies were centrally designated by the European
Commission among EU members [73] and EU Candidate countries to a lesser extent [74]. The lasting
macroeconomic crisis effects, between 2007 and 2016, contributed significantly to the worsening
of health financing sustainability. A recent Brookings Institute report, based on World Bank data,
claims the beginnings of sustainable global economic growth in 2017 and 2018 [75]. Their estimates
are that one half of this real GDP growth, worldwide, remains to be driven by seven major Emerging
Markets or EM7 (BRICS + Mexico, Indonesia and Turkey), while only a quarter by G7 nations on the
time horizon 2017–2020 [76]. These promising signs give hope for a European-wide ability to invest
more in health, which should be recovered in the near future. This refers to not only nominal and
purchasing power parity spending, but also percentage point share of real disposable GDP.
6. Conclusions
Regardless of some grounds for optimism, there is a prevailing consensus among health policy
authorities in the EU and Eurasian Union, CIS and WHO Europe alike, that health financing efficiency
will have to be substantially improved. The core underlying assumption of all European health system
establishments, since their late XIX century creation, was a demographic growth model. This postulate
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has now changed in Europe and worldwide, with the advent and acceleration of global population aging.
A shrinking workforce and contracted tax base in the labor market are constraining the supply-side
of modern-day societies’ ability to invest in medical care. The demand-side is burdened by the
spreading of non-communicable diseases, demand for long-term, home-based care, family caregiving
and prohibitively expensive last-year-of-life, amounting to the entire lifetime medical consumption of a
citizen. Given these core drivers in the equation, technological innovation in medicine, and consecutive
public demand for cutting-edge technologies remain far less containable areas by cost-effective resource
allocation policies. These challenges, alongside fiscal constraints, are shared across the East and West
of the European continent in the long run. Hopefully, these vast regions will be able to learn from each
other’s distinctive historical experiences and create more adaptive system responses in the future.
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